Report Company Directory
- ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights by GlobeNewsWire
- ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 by GlobeNewsWire
- ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease by GlobeNewsWire
- ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 by GlobeNewsWire
- ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Su by GlobeNewsWire
- ACELYRIN, INC. to Participate in Upcoming Investor Conferences by GlobeNewsWire
- ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results by GlobeNewsWire
- ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 by GlobeNewsWire
- ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 by GlobeNewsWire
- ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 by GlobeNewsWire